Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 1Dermatologic 1CNS 1

Conditions

Melanoma 1Gliosarcoma 1Glioblastoma 1

Interventions

Cyclophosphamide 641Bevacizumab 552Paclitaxel 534Carboplatin 533Cisplatin 480pembrolizumab 456Gemcitabine 422Docetaxel 415Rituximab 386Radiotherapy 373Dexamethasone 351Doxorubicin 330Nivolumab 308Fluorouracil 286Capecitabine 260Etoposide 245Prednisone 244Oxaliplatin 242Erlotinib Hydrochloride 242Cytarabine 233Lenalidomide 232Trastuzumab 226Pemetrexed 220Vincristine 212fludarabine phosphate 208Leucovorin 208Cetuximab 208Filgrastim 204Bortezomib 193Methotrexate 183

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Has results × Molecular Targeted Therapy × Clear all
NCT03020017 2022-08-26

NU-0129 in Treating Patients With Recurrent Glioblastoma or Gliosarcoma Undergoing Surgery

Northwestern University

Phase EARLY_PHASE1 Completed
8 enrolled 11 charts
CNSSarcoma

Glioblastoma, Gliosarcoma

NCT02094872 2020-01-02

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

Yale University

Phase 2 Completed
49 enrolled 8 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡